TRANSGENE (EPA:TNG) | Finanzwire

BRIEF

published on 06/13/2025 at 08:35, 7 months 17 days ago

Transgene Engages with Key Biotech Industry Platforms

Cancer Treatment Clinical Data Immunotherapy Transgene Biotech Meetings
PRESS RELEASE

published on 06/13/2025 at 08:30, 7 months 17 days ago

Transgene to Participate in Upcoming Meetings with Biotech Industry Leaders
Transgene to participate in upcoming meetings with biotech industry leaders to discuss positive clinical data on neoantigen cancer vaccine TG4050 and present innovative immunotherapies. Learn more at www.transgene.com

Biotech Industry Clinical Data Transgene Immunothérapies Neoantigen Cancer Vaccine
BRIEF

published on 06/01/2025 at 19:20, 7 months 28 days ago

Transgene and NEC: Promising progress with the TG4050 vaccine

Immunotherapy Transgene Therapeutic Vaccine Clinical Phase Neoantigens
PRESS RELEASE

published on 06/01/2025 at 19:15, 7 months 28 days ago

Transgene and NEC Present Durable Disease-Free Survival and Sustained T Cell Responses at 24 Months with Individualized Cancer Vaccine TG4050
Transgene and NEC reveal positive data on TG4050 cancer vaccine, demonstrating durable disease-free survival and sustained T cell responses at 24 months in HPV-negative head and neck cancer. Conference call on June 6, 2025

Cancer Vaccine Transgene TG4050 ASCO 2025 NEC
BRIEF

published on 05/22/2025 at 17:50, 8 months 7 days ago

Transgene to Present Phase I Data on Cancer Vaccine TG4050 at ASCO 2025

Cancer Vaccine Transgene TG4050 ASCO 2025 Phase I Data
PRESS RELEASE

published on 05/22/2025 at 17:45, 8 months 7 days ago

Transgene to Present 24-month Disease-Free Survival Data from All Patients in Phase I Part of Trial of Individualized Cancer Vaccine, TG4050, at ASCO 2025
Transgene to present 24-month disease-free survival data from all patients in Phase I part of trial of individualized cancer vaccine, TG4050, at ASCO 2025

Cancer Vaccine Transgene TG4050 ASCO 2025 Disease-free Survival
BRIEF

published on 04/10/2025 at 20:20, 9 months 19 days ago

Transgene makes available the 2024 Universal Registration Document

AMF Social Responsibility Immunotherapy Registration Document Transgene
PRESS RELEASE

published on 04/10/2025 at 20:15, 9 months 19 days ago

Availability of Transgene’s 2024 Universal Registration Document (URD)
Transgene announces availability of its 2024 Universal Registration Document (URD) containing financial reports and ESG factors. French & English versions can be accessed online

Financial Reports Transgene ESG Factors 2024 Universal Registration Document French Version
BRIEF

published on 03/27/2025 at 17:50, 10 months 2 days ago

Transgene: major advances and outlook for 2025

Immunotherapy Head And Neck Cancer 2024 Financial Results TG4050 Vaccine Myvac® Platform
PRESS RELEASE

published on 03/27/2025 at 17:45, 10 months 2 days ago

Transgene Achieves Key Milestones in 2024, Including Clinical Proof of Principle for Individualized Cancer Vaccine ? Strong Outlook for 2025
Transgene achieves key milestones in 2024, including clinical proof of principle for individualized cancer vaccine TG4050, with strong outlook for 2025. New trial planned in Q4 2025 for a second indication

Milestones Cancer Vaccine Transgene 2025 Outlook Clinical Proof

Published on 01/30/2026 at 08:35, 34 minutes ago

Alaska Energy Metals Announces Closing Of Life Offering of Units
Published on 01/30/2026 at 08:00, 1 hour 9 minutes ago

Troubadour Resources Intercepts Target Mineralization Near Surface during Phase 1 of the Multi-Phase Drill Program at Senneville Gold-Silver-Copper Property
Published on 01/30/2026 at 02:15, 6 hours 54 minutes ago

Canex Metals Announces Success of Gold Basin Take-Over Bid, Extension of the Partial Revocation of the Cease-Trade Order Imposed on Gold Basin, Waiver of All Remaining Conditions, Initiation of the Share Take Up Process, and Mandatory 10-Day Extension
Published on 01/30/2026 at 00:00, 9 hours 9 minutes ago

LIR Life Sciences Reports Positive Interim Preclinical Results from Comparative Animal Study of Novel CPP-Enabled Transdermal Delivery of GLP/GIP-Based Therapies
Published on 01/29/2026 at 23:00, 10 hours 9 minutes ago

PPX Mining Announces Filing of 2025 Audited Financial Statements and MD&A

View all ACCESSWIRE

Published on 01/30/2026 at 08:29, 40 minutes ago

Notice of Early Redemption
Published on 01/30/2026 at 08:00, 1 hour 9 minutes ago

Ørsted to present its annual report for 2025 on February 6
Published on 01/30/2026 at 08:00, 1 hour 9 minutes ago

Transaction in Own Shares
Published on 01/30/2026 at 08:00, 1 hour 9 minutes ago

Aquis Stock Exchange: Admission to trading
Published on 01/30/2026 at 07:29, 1 hour 40 minutes ago

Consolidated profit (excluding Russia) above 1.4 billion euros

View all EQS

Published on 01/30/2026 at 08:00, 1 hour 9 minutes ago

AMA: 4th Quarter & FY 2025 Revenues
Published on 01/29/2026 at 18:00, 15 hours 9 minutes ago

GUILLEMOT CORPORATION: FULL-YEAR 2025 CONSOLIDATED TURNOVER UP 2%
Published on 01/29/2026 at 17:45, 15 hours 24 minutes ago

LANSON-BCC ANNOUNCES 2025 REVENUES AND FINALISES THE ACQUISITION OF HEIDSIECK & C° MONOPOLE
Published on 01/29/2026 at 17:45, 15 hours 24 minutes ago

Cegedim generated LFL revenue growth of 1.1% in 2025
Published on 01/29/2026 at 17:40, 15 hours 29 minutes ago

ALTEN: Annual revenue 2025

View all LES ECHOS COMFI WIRE

News